The Department of Experimental and Clinical Medicine ofUniversity of Magna Graecia Of Catanzaro He is among the winners of the eighth edition of the “Roche Foundation for Independent Research” Call. With a total investment of 350 thousand euros for the financing of seven projects presented by researchers under 40, the announcement rewarded the University of Catanzaro by allocating 50 thousand euros for the development of an innovative project in the field of immunotherapy against blood cancer.
Author of the research project “Development of an immunotherapy precision strategy against B cells neoplasms through an agnostic platform” is Daniele Caraccioloassociated professor of blood diseases of the Magna Graecia University of Catanzaro. Commenting on the winning study said: “The hypothesis of this project is that the discovery of new therapeutic targets on the surface of cancer cells can represent an important clinical opportunity for the development of personalized immunotherapy against blood neoplasms such as leukemias, lymphomas and myelomas. The goal is, therefore, to instruct our immune system to selectively destroy the tumor cells that express these new ones therapeutic targets “.
Professor Daniele Caracciolo
Since its launch to date, the “Roche Foundation for independent research” call has allocated 4.3 million euros, establishing itself as one of the most successful initiatives in this area: more than 2,600 projects have been candidate over the years and 63 those financed so far.
“Investing in talent and believing in young researchers means betting on the future of our country. In the Roche Foundation we are convinced that supporting independent research is a strategic lever to grow the Italian system – said Mariapia Garavaglia, president of Fondazione Roche – it is our duty to continue looking for innovative solutions that concretely improve the life of people, responding with vision and courage to the new challenges of health”.
On May 5, the candidates for the new edition of the announcement opened. It will be possible to present the projects – in English – until 1 August 2025, exclusively through the website www.rocheperlarcarca.it. The new edition also provides that the projects are presented by Italian public or private bodies, without profit, and by IRCCS. The person in charge of the research project (PI, Principal Investigator) must be less than 40 years old. Support to young researchers operating in Italy also translates this year into a funding of 350 thousand euros, intended for seven research projects in five therapeutic areas: oncology, oncological hematology, ophthalmology, neuroscience and hereditary coagulation diseases. Confirmed Springer Nature, leader in the world of research and scientific education and guarantor of impartiality and thirdness, as an evaluator body.